Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;29(12):7563-7568.
doi: 10.1007/s00520-021-06331-5. Epub 2021 Jun 12.

Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience

A Taliansky  1   2 , O Furman  3 , M Gadot  3 , D Urban  3   4 , J Bar  3   4 , R Shapira-Frumer  3   4 , B Kaufman  3   4 , N Asher  3   4 , R Leibowitz-Amit  3   4 , A Itay  3   4
Affiliations

Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience

A Taliansky et al. Support Care Cancer. 2021 Dec.

Abstract

Background: Treatment with immune checkpoint inhibitors (ICI) has greatly improved survival for patients with a number of malignant diseases in recent years. Neurological immune-related adverse events (n-irAE) of varying severity have been reported in the literature. We aimed to identify the incidence of n-irAE, focusing on immune-related encephalitis (IRE), in patients treated with ICI for multiple non-hematological malignancies in our institution.

Methods: All patients with histologically verified cancer that received treatment with ICI at the Sheba Medical Center between January 2017 and August 2019 were surveyed. Medical records for each patient were reviewed and information regarding n-irAE was recorded.

Results: In total, 1993 patients were included. Eleven cases of IRE were recorded, affecting 0.55% of patients overall, eight had non-melanoma cancer. Eight patients had made a full recovery.

Conclusions: IRE is a n-irAE more frequent than previously reported, particularly in non-melanoma patients. The diagnostic criteria and optimal treatment needs to be determined. ICI re-challenge after IRE can be considered for selected patients.

Keywords: Autoimmune encephalitis; Immune checkpoint inhibitor adverse event; Immune checkpoint inhibitor–related encephalitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481. - DOI - PubMed
    1. Dalmau J. Looks can be deceiving: A B-cell–mediated encephalopathy with normal MRI? Neurol - Neuroimmunol Neuroinflammation. 2018;5(3):e461. doi: 10.1212/NXI.0000000000000461. - DOI - PMC - PubMed
    1. Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017;13(12):755–763. doi: 10.1038/nrneurol.2017.144. - DOI - PubMed
    1. Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—opportunities and challenges. Drug Resist Updat. 2017;2017(30):39–47. doi: 10.1016/j.drup.2017.02.001. - DOI - PubMed
    1. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi: 10.1038/s41571-019-0218-0. - DOI - PubMed

Substances